Emergent's Spinoff Aptevo Therapeutics Announces Management Team

From DCAT Value Chain Insights (VCI)

By People On The Move posted 01-27-2016 05:50


Emergent BioSolutions Inc., a specialty pharmaceutical company, announced the anticipated executive management team of Aptevo Therapeutics Inc., Emergent’s planned biosciences business spin-off company. Members of the Aptevo executive management team will be appointed to their positions effective upon completion of the tax-free spin-off of Aptevo, expected to occur in mid-2016.

As previously announced, Marvin L. White will serve as Aptevo’s chief executive officer upon the expected completion of the spin-off. He will be joined on the executive management team by the following individuals: Jeff Lamothe, senior vice president and chief financial officer (CFO); Scott C. Stromatt, chief medical officer and senior vice president, clinical development and medical affairs; Jane Gross, vice president, research and non-clinical development; Mike Adelman, vice president, commercial operations; and Shawnte Mitchell, vice president and general counsel.

Mr. White is currently a member of Emergent BioSolutions’ board of directors. He is the former CFO of St. Vincent’s Health, a $2.8 billion multi-hospital health system. Mr. White previously served as Executive Director and CFO of Lilly USA, a subsidiary of Eli Lilly and Company and held other positions in corporate finance at Eli Lilly and Company. He serves on the boards of CoLucid Pharmaceuticals, Inc., WP Glimcher, and OneAmerica Financial Partners Inc.

Mr. Lamothe will lead finance, business development, investor relations, and IT. He currently serves as Emergent’s vice president of finance, Biosciences Division. Mr. Lamothe assumed this role in 2014 when Emergent concluded the acquisition of Cangene Corporation, where he was CFO. Mr. Lamothe's business experience is built on a 25+ year career, spanning several industries in both CFO and CEO roles.

Dr. Stromatt will continue as the chief medical officer at Aptevo, a position he has held for the last seven years at Emergent. He will lead clinical research, medical affairs, parmacovigilance, and regulatory affairs, and will continue the clinical development programs for the ADAPTIR molecules that he has designed and directed. Dr. Stromatt has nearly three decades of experience at biotechnology and pharmaceutical companies, including being a biotechnology analyst for Wall Street investment firm C.E. Unterberg. Dr. Stromatt has conducted over 55 clinical trials in a wide variety of indications, including oncology, rheumatology, pulmonology, gastroenterology, and neurology.

Dr. Gross will continue to lead research and non-clinical development, a position she has held for the last five years at Emergent. She will lead research efforts in molecular biology and protein engineering, immunology, protein and cell sciences, and translational research for clinical development. Dr. Gross has a Ph.D. in Immunology and over twenty-five years of experience in the discovery and development of novel protein therapeutics in autoimmune, infectious disease and oncology indications and is an inventor on over 100 patents. Prior to joining Emergent, Dr. Gross served as vice president of immunology research at ZymoGenetics Inc., where she led efforts in discovery and development of therapeutics from novel genes for treatment of AIID and cancer.

Mr. Adelman will continue to lead all commercial functions at Aptevo as vice president, commercial operations, a position that he has held since 2012 at Cangene Corporation, which was acquired by Emergent in 2014. Mr. Adelman brings over 20 years of industry-specific commercial leadership experience in areas, including sales, marketing, contracting, pricing, commercial analytics, and alliance management. Prior to joining Cangene, Mr. Adelman was vice president of marketing and sales at Adolor Corporation and senior director, marketing strategy at AstraZeneca.

Ms. Mitchell will lead governance, SEC, intellectual property, contracts, and compliance. She is currently vice president, associate general counsel and assistant secretary of Emergent, where she provides strategic legal advice in a variety of areas, including corporate governance, healthcare regulatory, and product development, and has served as lead negotiator on various transactions. Prior to Emergent, Ms. Mitchell was an associate at Ropes & Gray LLP, where she advised healthcare, life sciences, and technology clients in mergers and acquisitions, venture capital investment, and debt transactions.

Source: Emergent BioSolutions


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription